HCAT
Health Catalyst, Inc. Healthcare - Health Information Services Investor Relations →
Health Catalyst, Inc. (HCAT) closed at $1.23 as of 2026-03-20, trading 84.5% below its 200-week moving average of $7.92. This places HCAT in the extreme value zone. The stock is currently moving closer to the line, down from -83.5% last week. With a 14-week RSI of 24, HCAT is in oversold territory.
Trading volume is running at 1.6x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.84 ratio) is neutral — neither side is clearly dominating.
Over the past 299 weeks of data, HCAT has crossed below its 200-week moving average 3 times. On average, these episodes lasted 77 weeks. Historically, investors who bought HCAT at the start of these episodes saw an average one-year return of +78.2%.
With a market cap of $91 million, HCAT is a small-cap stock. The company generates a free cash flow yield of 11.9%, which is notably high. Return on equity stands at -58.3%. The stock trades at 0.4x book value.
Share count has increased 30.3% over three years, indicating dilution. This stock also meets the Yartseva multibagger criteria as a small-cap with strong free cash flow yield and reasonable book value.
Over the past 5.8 years, a hypothetical investment of $100 in HCAT would have grown to $4, compared to $229 for the S&P 500. HCAT has returned -42.2% annualized vs 15.2% for the index, underperforming the broader market over this period.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: HCAT vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After HCAT Crosses Below the Line?
Across 3 historical episodes, buying HCAT when it crossed below its 200-week moving average produced an average return of +28.3% after 12 months (median +69.0%), compared to +21.0% for the S&P 500 over the same periods. 67% of those episodes were profitable after one year. After 24 months, the average return was -64.3% vs +15.0% for the index.
Each line shows $100 invested at the moment HCAT crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
HCAT has crossed below its 200-week MA 3 times with an average 1-year return of +78.2% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jun 2020 | Jul 2020 | 1 | 6.6% | +88.9% | -95.9% |
| Aug 2020 | Sep 2020 | 4 | 5.4% | +67.5% | -96.1% |
| Nov 2021 | Ongoing | 225+ | 84.5% | Ongoing | -96.8% |
| Average | 77 | — | +78.2% | — |
Frequently Asked Questions
Is HCAT below its 200-week moving average?
Yes. As of 2026-03-20, Health Catalyst, Inc. (HCAT) is trading 84.5% below its 200-week moving average of $7.92. The current price is $1.23.
What is HCAT's 200-week moving average price?
Health Catalyst, Inc.'s 200-week moving average is $7.92 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when HCAT drops below its 200-week moving average?
HCAT has crossed below its 200-week moving average 3 times in our data. On average, buying at that moment produced a one-year return of +78.2%. These dips have historically been decent entry points. These episodes lasted 77 weeks on average.
Is HCAT a good value right now?
Here's what our data says about HCAT as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 24 (oversold). Free cash flow yield is 11.9%. Return on equity is -58.3%. Price-to-book is 0.4x. This is not a buy or sell recommendation — always do your own research.
How does HCAT compare to the S&P 500?
Over the past 5.8 years, $100 invested in HCAT would have grown to $4, compared to $229 for the S&P 500. That's -42.2% annualized vs 15.2% for the index. HCAT has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20